Expansion planned of 'Russia first' policy towards drug manufacturers

22 May 2017

The policy of putting Russian drug manufacturers before foreign firms was one of many issues discussed during the Adam Smith Institute’s Russian Pharmaceutical Forum last week.

More than 600 people took part in the two-day forum, including 100 representatives of pharmaceutical companies, government and other experts, with their presentations and discussions covering global trends in pharma, advantages of the Eurasian Economic Union and other topics.

Viktor Dmitriev, chief executive of trade group the Association of Russian Pharmaceutical Manufactures (ARPM), held an interview session with Sergey Tsyb, Russia’s Deputy Minister of Industry and Trade of the Russian Federation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK